See more : Zee Media Corporation Limited (ZEEMEDIA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Eloxx Pharmaceuticals, Inc. (ELOX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eloxx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kootenay Silver Inc. (KOOYF) Income Statement Analysis – Financial Results
- T-Gaia Corporation (3738.T) Income Statement Analysis – Financial Results
- Wuhan YZY Biopharma Co Ltd (2496.HK) Income Statement Analysis – Financial Results
- Banque Cantonale de Genève SA (0RMP.L) Income Statement Analysis – Financial Results
- Scodix Ltd. (SCDX.TA) Income Statement Analysis – Financial Results
Eloxx Pharmaceuticals, Inc. (ELOX)
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,871,400.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.73M | 45.57M | 14.59M | 26.35M | 20.49M | 16.40M | 733.66K | 2.18M | 4.57M | 3.34M | 2.09M | 2.57M | 3.72M | 2.64M | 2.35M | 1.76M | 1.21M | 1.57M | 1.42M | 1.15M | 793.90K | 370.19K | 479.47K | 476.46K | 173.46K | 0.00 | 0.00 |
| General & Administrative | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34M | 1.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.72K | 574.35K | 0.00 | 0.00 | 0.00 |
| SG&A | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 2.35M | 2.21M | 2.29M | 2.41M | 1.92M | 2.03M | 2.91M | 1.48M | 1.94M | 1.49M | 1.97M | 982.40K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -115.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.37K | -7.81K |
| Operating Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Cost & Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Interest Income | 274.00K | 8.00K | 337.00K | 1.07M | 601.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.48K | 0.00 | 0.00 | 43.08K | 100.45K | 69.30K | 0.00 | 54.03K | 0.00 | 0.00 | 24.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.95M | 1.26M | 1.41M | 1.62M | 7.00K | 43.00K | 265.20K | 533.00 | 2.77K | 77.44K | 119.09K | 134.55K | 88.12K | 610.67K | 1.01M | 434.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 695.00K | 960.00K | 571.00K | 559.00K | 216.00K | 39.00K | 44.08K | 93.39K | 177.07K | 349.66K | 293.63K | 258.02K | 143.27K | 126.57K | 111.75K | 96.85K | 166.17K | 40.11K | 43.72K | 30.42K | 38.70K | 24.36K | 24.16K | 18.71K | 4.00K | 0.00 | 0.00 |
| EBITDA | -33.37M | -66.02M | -33.46M | -50.56M | -46.15M | -20.39M | -4.59B | -8.85M | -17.88M | -8.80M | -4.65B | -4.83M | -6.33B | -4.72M | -4.17M | -3.50M | -3.15M | -3.38M | -3.28M | -4.01M | -2.23M | -2.09M | -1.95M | -2.43M | -1.15M | -10.37K | -7.81K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,827.52% | -9,982.48% | -6,572.38% | 0.00% | -2,491.85% | 0.00% | 2,290.26% | -1,343.62% | -620.45% | -1,051.61% | -5,068.89% | -2,853.45% | -25,703.22% | -23,608.61% | -1,120.21% | -200,724,000.00% | -242,873,500.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.42M | -66.02M | -33.46M | -50.56M | -47.57M | -20.39M | -4.59M | -11.19M | -18.08M | -9.15M | -4.65M | -5.41M | -7.92M | -4.85M | -4.28M | -3.60M | -3.32M | -3.42M | -3.32M | -4.04M | -2.27M | -2.11M | -1.97M | -2.45M | -1.16M | -10.37K | -7.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,926.64% | -24,102.31% | -9,147.80% | 0.00% | -2,705.76% | 0.00% | -3,461.80% | -1,558.07% | -788.11% | -1,107.00% | -5,129.06% | -2,657.39% | -24,223.34% | -22,686.06% | -1,057.12% | -197,107,000.00% | -244,744,800.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -709.00K | -1.12M | -319.00K | 502.00K | -824.00K | -2.24M | 2.25M | 12.95K | -77.44K | -1.47M | 345.40K | 649.73K | 4.85M | 4.28M | 3.60M | 3.32M | 3.42M | 1.13M | 959.02K | 130.95K | 150.55K | 60.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -36.07M | -66.73M | -34.58M | -50.87M | -47.06M | -21.21M | -6.84M | -8.95M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -12.77M | -4.76M | -4.27M | 0.00 | 0.00 | -3.03M | -3.76M | -2.14M | -1.96M | -1.91M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,930.57% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,123.46% | -1,731.89% | -934.55% | 0.00% | 0.00% | -2,426.36% | -22,560.92% | -21,376.54% | -981.84% | -191,073,900.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.26M | 1.41M | 1.62M | 122.00K | 43.00K | -1.04M | -680.00K | 2.77K | 77.44K | 119.09K | -24.26K | 1.07M | 8.54M | 1.44M | 1.00M | -69.30K | -104.46K | -342.82K | -310.35K | -202.27K | -174.81K | -94.08K | -2.53K | 13.14K | 10.37K | 7.81K |
| Net Income | -36.07M | -66.73M | -34.58M | -50.87M | -47.19M | -21.21M | -5.80M | -8.27M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -13.38M | -5.73M | -4.60M | -3.25M | -3.31M | -2.98M | -3.73M | -2.07M | -1.94M | -1.88M | -2.44M | -1.17M | -10.37K | -7.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,023.91% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,559.65% | -2,082.50% | -1,007.62% | -1,083.90% | -4,972.38% | -2,383.13% | -22,361.26% | -20,663.38% | -969.71% | -187,699,100.00% | -244,491,600.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| Weighted Avg Shares Out | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
| Weighted Avg Shares Out (Dil) | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
Barclays PLC Purchases 12,280 Shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX)
Barclays PLC grew its stake in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 93.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,438 shares of the company’s...
Eloxx Pharmaceuticals (OTCMKTS:ELOX) Receives Daily News Sentiment Score of 2.00
Headlines about Eloxx Pharmaceuticals (OTCMKTS:ELOX) have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than 6,000 blog and news sources in real time. The firm ranks coverage of publicly-traded...
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
Eloxx Pharmaceuticals (OTCMKTS:ELOX) Stock Rating Upgraded by Zacks Investment Research
Eloxx Pharmaceuticals (OTCMKTS:ELOX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage presently has a $3.50 price target on the stock. Zacks...
Citigroup Lowers Eloxx Pharmaceuticals (OTCMKTS:ELOX) Price Target to $11.00
Eloxx Pharmaceuticals (OTCMKTS:ELOX) had its target price decreased by Citigroup from $31.00 to $11.00 in a research note issued to investors on Monday, The Fly reports. The firm currently has a “neutral” rating on the stock. Citigroup‘s price target indicates...
Eloxx Pharmaceuticals (OTCMKTS:ELOX) Earns Neutral Rating from HC Wainwright
HC Wainwright restated their neutral rating on shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) in a research report sent to investors on Friday morning, The Fly reports. The brokerage currently has a $3.00 target price on the stock, down from their previous...
Zacks: Analysts Expect Senesco Technologies Inc. (NYSE:ELOX) Will Announce Earnings of -$0.36 Per Share
Analysts expect that Senesco Technologies Inc. (NYSE:ELOX) will post earnings of ($0.36) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Senesco Technologies’ earnings. The lowest EPS estimate is ($0.38) and the highest is...
Eloxx Pharmaceuticals (ELOX) Receives a Hold from H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Eloxx Pharmaceuticals (ELOX) today and set a price target of $3.00. The company's shares
Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2019 Earnings Call Transcript
ELOX earnings call for the period ending December 31, 2019.
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
Source: https://incomestatements.info
Category: Stock Reports